Idarubicinhydrochlorid Accord (Idarubicin Hydrochloride)

Idarubicin intercalates into DNA and stabilizes the topoisomerase II‑DNA complex, preventing the re‑ligation of DNA strands. This causes accumulation of double‑strand breaks, leading to apoptosis of malignant cells, particularly those that are rapidly proliferating.

The specific dose and schedule of Idarubicinhydrochlorid Accord are determined by the prescribing oncologist based on the patient’s clinical condition, disease stage, and treatment protocol. The prescriber sets the appropriate regimen for each individual case.

The safety of idarubicin in pregnancy and lactation has not been established. It is generally contraindicated unless the potential therapeutic benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Idarubicin is structurally related to daunorubicin and doxorubicin but has a higher lipophilicity, allowing better cellular uptake and potency against certain leukemic cells. It may be preferred in some AML protocols due to its activity profile, although cardiotoxicity risk remains comparable across the class.

The product must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Prior to use, inspect the solution for particulate matter or discoloration and follow aseptic techniques for intravenous preparation.

Idarubicinhydrochlorid Accord is supplied as an injectable solution for intravenous infusion. It is typically diluted in an appropriate carrier fluid and administered over a prescribed period under close clinical supervision, with monitoring for infusion‑related reactions.

The most serious risks include cardiotoxicity leading to heart failure, severe myelosuppression that can cause life‑threatening infections or bleeding, and acute infusion reactions such as hypotension or respiratory distress. Continuous cardiac and hematologic monitoring is essential during therapy.

Patients with pre‑existing severe cardiac disease, uncontrolled infections, known hypersensitivity to idarubicin or other anthracyclines, and those who are pregnant without a compelling therapeutic indication should not receive Idarubicinhydrochlorid Accord. Clinical judgment is required for each individual.